NCT04801511 (CORT) is a Phase 2 clinical trial of Vitamin C in Rectal Cancer, sponsored by Zhou Fuxiang.

Who is sponsoring NCT04801511?

NCT04801511 is sponsored by Zhou Fuxiang.

What drugs are being tested in NCT04801511?

Interventions in NCT04801511: Vitamin C.

What condition does NCT04801511 study?

NCT04801511 studies Rectal Cancer.

Is NCT04801511 still recruiting?

NCT04801511 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04801511: CORT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer

Status unknown Phase 2 Last updated 17 March 2021

What this trial tests

Phase 2 trial testing Vitamin C in Rectal Cancer in 60 participants. Status unknown.

Timeline

8 March 2021

Primary endpoint
30 June 2023

31 December 2024

Quick facts

Lead sponsor	Zhou Fuxiang
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	8 March 2021
Primary completion	30 June 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Vitamin C — full drug profile →

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

Zhou Fuxiang — full company profile →

Who can join

Adults 18 to 70, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (IMRT) with concurrent high-dose intravenous vitamin C and mFOLFOX6 in locally advanced rectal cancer patients.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy.
Wang J, Sun D, Huang L, Wang S, et al · · 2021 · cited 38× · PMID 34539975 · DOI 10.1155/2021/8532940
Oxidative Stress and Age-Related Tumors.
Di Carlo E, Sorrentino C. · · 2024 · cited 33× · PMID 39334768 · DOI 10.3390/antiox13091109
Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment.
Maekawa T, Miyake T, Tani M, Uemoto S. · · 2022 · cited 16× · PMID 36203466 · DOI 10.3389/fonc.2022.981547

Verify or expand the search:

Other trials of Vitamin C

Trials testing the same drug.

NCT07476443 — Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity · Phase 2, PHASE3 · not yet recruiting
NCT07414693 — Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia · Phase 4 · recruiting
NCT06971315 — Impact of Vitamin C on Pain Detection and Tolerance Threshold · NA · completed
NCT06794255 — Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults · NA · recruiting
NCT07341308 — Does Vitamin C Increase the Body Heat Generated By The Nervous System? · NA · recruiting

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Zhou Fuxiang trials

Trials by the same sponsor.

NCT05240690 — Umbilical Cord Blood Derived MAK Immune Cells Combined With Standard Second-Line Treatments for Hepatobiliary and Pancre · Phase 1 · unknown
NCT05004441 — Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer · Phase 2 · unknown
NCT03154983 — The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gas · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04801511 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhou Fuxiang
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing